We aspire to keep the wonderful world visible for all

Welcome to Revenio's investor website

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with its operating profit standing at 28.1%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Latest report

January-June Half-Year Financial Report 2022

null

Upcoming event

Audiocast for Half-year report, August 4 at 3 p.m. EEST

Press releases

IR contacts

CFO Robin Pulkkinen robin.pulkkinen(at)revenio.fi

Share price {{stockPriceLatestDate}}: {{stockPrice}} {{currency}}

Revenio is listed on Nasdaq Helsinki

Analyses

Revenio is followed by Carnegie, Inderes, OP and SEB